SEPN 8-K: Company Announces Q2 2025 Results; Press Release Attached

Rhea-AI Filing Summary

Septerna, Inc. announced that it released its financial results and business highlights for the quarter ended June 30, 2025 and furnished the related press release as Exhibit 99.1 to this Current Report. The filing states the press release is being furnished (and not "filed") for purposes of the Exchange Act, and the 8-K itself does not include detailed financial statements or metrics. Readers should consult Exhibit 99.1 for the substantive results and disclosures.

Insights

Financial Analyst

TL;DR: Routine earnings press release furnished; no financial metrics are included in this 8-K.

The 8-K notifies investors that Septerna furnished a press release with results and business highlights for the quarter ended June 30, 2025, and that the press release is attached as Exhibit 99.1. The filing explicitly states the material is "furnished" rather than "filed," which limits the document's incorporation and Section 18 liability. Because the 8-K contains no financial figures or performance metrics, this document alone does not allow assessment of revenue, profit, or cash-flow trends.

Corporate Governance Expert

TL;DR: Standard disclosure practice; no governance or material transaction items disclosed here.

This Form 8-K serves to furnish a corporate press release; it does not report executive changes, material agreements, or other governance actions. The filing includes a signature from the CEO and references Exhibit 99.1 for the substantive content. From a governance and disclosure perspective, the document is routine and contains no additional material events beyond the announcement of quarterly results.

0001984086false00019840862025-08-112025-08-11

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 11, 2025

Septerna, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-42382	84-3891440
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
250 East Grand Avenue
South San Francisco, California				94080
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: 650 338-3533

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		SEPN		The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On August 11, 2025, Septerna, Inc. (the “Company”) announced its financial results and business highlights for the quarter ended June 30, 2025. A copy of the press release issued in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report of Form 8-K.

The information included under Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

99.1		Press Release issued by Septerna, Inc. on August 11, 2025, furnished herewith.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			Septerna, Inc.
Date:	August 11, 2025	By:	/s/ Jeffrey Finer, M.D., Ph.D.
			Jeffrey Finer, M.D., Ph.D. Chief Executive Officer

FAQ

What did Septerna (SEPN) disclose in this Form 8-K?

The company announced its financial results and business highlights for the quarter ended June 30, 2025 and furnished the related press release as Exhibit 99.1.

Where can I find Septerna's detailed quarterly results for Q2 2025?

Detailed results are included in the press release furnished as Exhibit 99.1 to the Form 8-K; the 8-K text does not contain the detailed financial metrics.

Does this 8-K include financial statements or tables?

No. The filing furnishes a press release and does not include financial statements or numerical financial tables within the 8-K itself.

Is the information in this 8-K considered "filed" under the Exchange Act?

No. The filing explicitly states the information and Exhibit 99.1 are being furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act.

Who signed the 8-K for Septerna?

The report is signed on behalf of Septerna by Jeffrey Finer, M.D., Ph.D., Chief Executive Officer.